Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
1,785 people get ILMN articles and Market Currents by email alert.
Get email alerts on ILMN »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
Business Wire (Thu, 6:30AM)
-
Business Wire (Wed, 6:30AM)
-
Business Wire (May 1, 2013)
-
Business Wire (Apr 25, 2013)
-
-
Illumina Flexes Its Muscles A BitStephen Simpson • Tue, Apr 23 -
Business Wire (Apr 22, 2013)
-
Business Wire (Apr 22, 2013)
-
-
-
-
-
-
-
Business Wire (Apr 8, 2013)
-
-
Business Wire (Apr 4, 2013)
-
-
Illumina Flexes Its Muscles A BitStephen Simpson • Tue, Apr 23
-
-
-
-
-
Roche Is Back; Buyout Leak Is UnsurprisingPropThink • Thu, Dec 20, 2012
-
-
-
-
Illumina Stays Independent But Drops As Roche's Offer ExpiresThe Burrill Report • Sun, Apr 22, 2012 -
-
-
-
Illumina - 3 Times Is Lucky?The Value Investor • Thu, Jan 26, 2012
-
Illumina Has Very Small Upside At These LevelsIvan Mutaftchiev • Thu, Jan 26, 2012 -
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Thursday Options Brief: HLF, ILMN & WSMInteractive Brokers • Thu, Dec 20, 2012
-
-
-
-
-
-
Illumina Management Discusses Q3 2012 Results - Earnings Call TranscriptTue, Oct 23, 2012
-
Illumina Management Discusses Q2 2012 Results - Earnings Call TranscriptWed, Jul 25, 2012
-
Illumina's CEO Discusses Q1 2012 Results - Earnings Call TranscriptMon, Apr 23, 2012 • 1 Comment
-
Illumina's CEO Discusses Q4 2011 Results - Earnings Call TranscriptWed, Feb 8, 2012
-
Illumina's CEO Hosts Illumina Transaction Conference Call (Transcript)Wed, Jan 25, 2012
-
Illumina's CEO Discusses Q3 2011 Results - Earnings Call TranscriptTue, Oct 25, 2011
-
Illumina's CEO Discusses Q2 2011 Results - Earnings Call TranscriptWed, Jul 27, 2011
-
Illumina's CEO Discusses Q1 2011 Results - Earnings Call TranscriptWed, Apr 27, 2011
-
Illumina's CEO Discusses Q4 2010 Results - Earnings Call TranscriptWed, Feb 9, 2011 • 1 Comment
-
Illumina CEO Discusses Q3 2010 Results - Earnings Call TranscriptTue, Oct 26, 2010
-
Illumina Q1 2010 Earnings Call TranscriptThu, Apr 29, 2010
-
Illumina, Inc Q4 2009 Earnings Call TranscriptThu, Feb 4, 2010
-
Illumina Q3 2009 Earnings Call TranscriptWed, Oct 28, 2009
-
Illumina, Inc. Q2 2009 Earnings Call TranscriptWed, Jul 22, 2009
-
Illumina, Inc. Q1 2009 Earnings Call TranscriptWed, Apr 22, 2009
-
Illumina Inc. Q4 2008 Earnings Call TranscriptTue, Feb 3, 2009
-
Illumina Inc. Q3 2008 Earnings Call TranscriptTue, Oct 21, 2008
-
Business Wire (Thu, 6:30AM)
-
Business Wire (Wed, 6:30AM)
-
Business Wire (May 1, 2013)
-
Business Wire (Apr 25, 2013)
-
at CNBC.com (Apr 22, 2013)
-
Business Wire (Apr 22, 2013)
-
Business Wire (Apr 22, 2013)
-
at MarketWatch.com (Apr 16, 2013)
-
Business Wire (Apr 8, 2013)
-
Business Wire (Apr 4, 2013)
-
Business Wire (Mar 27, 2013)
-
Business Wire (Mar 21, 2013)
-
Business Wire (Mar 14, 2013)
-
Business Wire (Feb 21, 2013)
-
Business Wire (Feb 20, 2013)
-
at CNBC.com (Jan 28, 2013)
-
Business Wire (Jan 28, 2013)
-
Business Wire (Jan 15, 2013)
-
Business Wire (Jan 15, 2013)
ILMN vs. ETF Alternatives
Company Description
We are a leading developer, manufacturer, and marketer of integrated systems for the analysis of genetic variation and biological function. We were incorporated in California in April 1998 and reincorporated in Delaware in July 2000. Our principal executive offices are located at 9885 Towne... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Thursday, January 26, 2012, 8:20 AM Illumina (ILMN) adopts a poison pill in a bid to stop a takeover by Roche (RHHBY.PK). The rights plan is triggered if a 15% ownership target is hit. Shares of ILMN -1.5%. 3 Comments [M&A, On the Move, Healthcare]
- Wednesday, January 25, 2012, 1:43 PM With Illumina (ILMN +44.8%) shares trading 23% above Roche's (RHHBY.PK) $44.50/share hostile bid price, investors clearly expect a better offer to arrive. Auriga (Buy) considers Roche's initial offer an "opportunistic" move spurred by Illumina's recent woes, and believes a stabilizing business will force Roche to make a higher bid. (more) Comment! [Healthcare, On the Move, M&A]
- Wednesday, January 25, 2012, 11:17 AM Roche’s (RHHBY.PK) $5.7B hostile offer for Illumina (ILMN +43.1%) is built on a loophole in ILMN’s takeover defenses: Roche will be able to vitiate ILMN’s provision for a staggered board by simply proposing to amend the by-laws at the next annual meeting to add another two Roche-sponsored directors, a scenario it completed successfully in its 2007 bid for Ventana. Comment! [M&A, Healthcare, On the Move]
-
Wednesday, January 25, 2012, 9:00 AM
Premarket gainers: ILMN +39%. PACB +21%. CA +16%. NBG +10%. TXT +9%. AAPL +9%. TPX +9%. LCC +7%. LIFE +7%. TQNT +6%. CRUS +6%. DAL +6%. RDN +5%. ZNGA +4%. WLT +4%. BRCM +4%.
Losers: FBC -24%. REDF -16%. ERIC -15%. FIO -12%. GLW -10%. ALU -9%. WLP -5%. AMD -4%. NVS -4%. WPZ -4%. NVDA -4%. MT -3%. ING -3%. Comment! [On the Move] - Wednesday, January 25, 2012, 7:52 AM Roche's $44.50/share bid for Illumina (ILMN) is lifting shares of the DNA-tech company and its peers. Illumina +40.6% to $52.99. Pacific Biosciences of California (PACB) +26.6%. Complete Genomics (GNOM) +23.6%. Life Technologies (LIFE) +8.5%. Comment! [Healthcare, On the Move]
- Tuesday, January 10, 2012, 1:43 PM While Illumina (ILMN +3.9%) has rebounded from the weakness caused by Life Technologies' (LIFE +7.2%) product announcement, smaller rival Complete Genomics' (GNOM -19.9%) bloodletting worsens as the day progresses. On Monday, the company announced it delivered 300 fewer genomes in Q4 than previously expected, news that triggered a downgrade from Oppenheimer. Comment! [Healthcare, On the Move]
- Tuesday, January 10, 2012, 12:49 PM After opening sharply lower on fears of new competition from Life Technologies, Illumina (ILMN -0.2%) has pared nearly all of the day's losses after announcing its HiSeq 2500 DNA sequencing system. Illumina claims the system, which will be available in 2H12, is capable of sequencing an entire genome in 24 hours, and will enable new applications for medical researchers. Comment! [Healthcare, On the Move]
- Tuesday, January 10, 2012, 9:54 AM Illumina (ILMN -7.5%) tails off on the open, as speculation picks up that Life Technologies may have beat it to the punch by bringing an affordable DNA reader to the market. Comment! [On the Move, Healthcare]
- Wednesday, January 4, 2012, 2:42 PM Illumina (ILMN +1.7%) says it's appointed Marc Stapley as CFO. Stapley, a former Pfizer VP, be responsible for overseeing finance, accounting, facilities and investor relations functions. Comment! [Healthcare, On the Move]
- Friday, October 7, 2011, 2:52 PM Illumina's (ILMN -32.2%) warning is taking a heavy toll on many companies dependent on medical research spending (I, II). Some of the other names tanking in sympathy: PKI -7.8%. LMNX -7.3%. TMO -5.7%. BRKR -3.5%. WAT -8%. PACB -11.4%. Fluidgm (FLDM -7.8%) is also among the casualties in spite of reaffirming its 2011 outlook. Comment! [Healthcare, On the Move]
- Friday, October 7, 2011, 9:52 AM Illumina (ILMN -32.8%) is crushed following its Q3 warning. Citi, which smartly downgraded shares in advance, is slashing its PT to $32, arguing Illumina's growth trajectory is now "called into question." Auriga is maintaining a Buy, citing Illumina's position in the next-gen DNA sequencing market. In addition to Life Sciences (LIFE -5.5% - previously), Affymetrix (AFFX -5.5%) is selling off on the news. Comment! [Healthcare, On the Move, Quick Ideas]
- Friday, October 7, 2011, 8:14 AM Another casualty from Illumina's (ILMN) preliminary Q3 report (previous): Shares of Life Technologies (LIFE) sink 11% premarket as heightened fears over diminishing revenue washes over companies that depend on robust academic research budgets. Comment! [On the Move]
- Friday, October 7, 2011, 8:02 AM Bruker (BRKR) falls 9% premarket after Illumina's (ILMN) Q3 earnings miss taints shares on the outlook for "sluggishness" in the U.S. academic market. Comment! [On the Move]
- Thursday, October 6, 2011, 5:23 PM Illumina (ILMN) falls 21.1% AH after the company announces preliminary Q3 revenue of ~$235M, below a consensus of $277.7M. Illumina blames the shortfall in part on delayed purchases as a result of uncertainty about research funding, and lower-than-expected sales of its HiSeq systems - possibilities Leerink Swann warned about last month. (earlier) 1 Comment [Healthcare, Earnings, On the Move]
- Thursday, October 6, 2011, 11:48 AM Illumina (ILMN -1.3%) trades lower after Citi downgrades the maker of DNA analysis chips to Hold, and lowers its PT to $44 from $90. The downgrade offsets a 13G filing from Scottish investment manager Baillie Gifford, stating the firm boosted its stake in Illumina in Q3 to nearly 10.1%. (previously) Comment! [Healthcare, On the Move]
- Thursday, September 15, 2011, 11:15 AM Ilumina (ILMN) is down 3.7% after Leerink Swann downgrades the company to Market Perform, and lowers its valuation range to $53-$57. The firm thinks the growth of Ilumina's high-end HiSeq genetic sequencing systems is decelerating over the short-term, and think NIH budget cuts could also hurt the company. Comment! [Healthcare, On the Move, Quick Ideas]
-
Alan Brochstein
$ILMN Sell Alert on 1/25 pre-market 55, Buy Alert on 4/18 pre-market 40, at "My Own Analyst" - View all 0 replies
-
- View all 1 replies
-
jowl: Started a position today regardless of how the meeting turns out tomorrow. Roche has always been willing to pay up, let's hope it continues
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
Michael Kudrna
EXPstocktrader: The Hepatitis C Gold Rush $IDIX $ILMN $INHX $MRK $VRUS $$ #biotech #KSMT http://bit.ly/zInIwE - View all 0 replies
-
- View all 1 replies
-
-
- View all 0 replies
-
- View all 2 replies
-
New Low Observer: classic move...didn't notice it before, but after the offer is made..."oh yeah, upgrade"...thanks RW Baird for the 20/20 hindsight... -
Holly Thompson: Doesn't it seem as if this happens most of the time...Makes me laugh when the piece comes out but almost always helps our stock.
-
- View all 0 replies
LATEST REPLIES